Brief: U.S. FDA Accepts Gilead’s Application For Investigational Once-Weekly Oral Yeztugo
Mon 21:34
BRIEF-U.S. FDA Accepts Gilead’s Application For Investigational Once-Weekly Oral Yeztugo June 15 (Reuters) - Gilead Sciences, Inc GILD.O:
U.S. FDA ACCEPTS GILEAD’S APPLICATION FOR INVESTIGATIONAL ONCE-WEEKLY ORAL YEZTUGO, POTENTIALLY THE FIRST LONG-ACTING PILL FOR HIV PREVENTION
GILEAD - FDA ACCEPTS SNDA FOR YEZTUGO ONCE-WEEKLY ORAL HIV PREP; PDUFA DATE FEB 2, 2027
Source text: ID:nBwbHT7f1a
Further company coverage: GILD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gilead Sciences,
See all newsBrief: U.S. FDA Accepts Gilead’s Application For Investigational Once-Weekly Oral Yeztugo
Factbox: Global drugmakers invest billions to boost US presence
Brief: Gilead Donates Remdesivir Vials to Uganda for Ebola Bundibugyo Virus Outbreak Response Efforts
Factbox: What Bundibugyo Ebola vaccines and treatments are under development
Factbox: Major deals involving US drugmakers and biotechs over the past decade